Interferon Gamma-1b by Inhalation for the Treatment of Patients With Cystic Fibrosis
Phase 1
Completed
- Conditions
- Cystic Fibrosis
- Registration Number
- NCT00043316
- Lead Sponsor
- InterMune
- Brief Summary
The purpose of this research study is to evaluate the safety and effectiveness of Interferon gamma-1b (IFN-g 1b) on lung function when given to patients with cystic fibrosis by inhalation (breathed into the lungs) three times a week for 12 weeks.
The FDA has not approved Interferon gamma-1b for use with cystic fibrosis patients, which is the condition being examined in this study.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 66
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method change in FEV1, sputum bacterial density 12 weeks
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie inhaled IFN-gamma-1b's effect on lung function in cystic fibrosis patients?
How does inhaled IFN-gamma-1b in Phase I/II trials compare to standard-of-care therapies for cystic fibrosis lung function improvement?
What biomarkers predict response to inhaled IFN-gamma-1b in NCT00043316 cystic fibrosis trials?
What adverse events and management strategies are associated with inhaled IFN-gamma-1b in cystic fibrosis Phase I/II trials?
What combination therapies or alternative immunomodulators show promise for cystic fibrosis alongside inhaled IFN-gamma-1b?